CARDIOMETABOLIC RISK FACTORS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS, LUPUS NEPHRITIS
https://doi.org/10.24884/1561-6274-2018-22-3-26-32
Abstract
This article provides an assessment of risk factors for early development of cardiovascular and metabolic disorders in children with systemic lupus erythematosus (SLE), lupus nephritis (LN). The contribution to the development of early disturbances of immune inflammation, metabolic imbalance, arterial hypertension, left ventricular hypertrophy, carotid intima-media thickness showed.
About the Authors
I. A. Kazyra
Belarussian State Medical University
Belarus
associate Professor, MD, PhD, Belarussian State Medical University 1st Department of Pediatrics
Belarus
associate Professor, MD, PhD, Belarussian State Medical University 1st Department of Pediatrics
A. V. Sukalo
Belarussian State Medical University
Belarus
prof., MD, PhD, DMedSci. Academic of National Balarus Academy of Sciences, Belarussian State Medical University 1st Department of Pediatrics
Belarus
prof., MD, PhD, DMedSci. Academic of National Balarus Academy of Sciences, Belarussian State Medical University 1st Department of Pediatrics
References
1. Quinlan C, Kary J, Pilkington C et al. The vascular phenotype of children with systemic lupus erythematosus. Pediatr Nephrol 2015; 30(8):1307–1316. doi: 10.1007/s00467-015-3059-9
2. Abou-Raya A, Abou-Raya S. Inflammation: a pivotal link between autoimmune diseases and atherosclerosis. Autoimmun Rev 2006;5(5):331–337
3. Ahmad Y, Shelmerdine J, Bodill H et al. Subclinical atherosclerosis in systemic lupus erythematosus (SLE): the relative contribution of classic risk factors and the lupus phenotype. Rheumatology (Oxford) 2007;46(6):983–988
4. Salgado A, Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012; 2012:849684. doi: 10.1155/2012/849684
5. Jordan N, Lutalo PM, D’Cruz DP. Novel therapeutic agents in clinical development for Systemic Lupus Erythematosus. BMC Medicine 2013; 11:120. doi: 10.1186/1741-7015-11-120
6. Edelbauer M., Kshirsagar S, Riedl M et al. Markers of childhood lupus nephritis indicating disease activity. Pediatr Nephrol 2011; 26 (3):401–410. doi: 10.1007/s00467-010-1720-x
7. Al M, Ng L, Tyrrell P et al. Adipokines as novel biomarkers in paediatric systemic lupus erythematosus. Rheumatology (Oxford) 2009;48(5):497–501. doi: 10.1093/rheumatology/kep030
8. Deedwania PC, Pedersen TR, DeMicco DA et al. TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol 2016; 1; 222:548–556. doi: 10.1016/j.ijcard.2016.07.201
9. Drozdz D1, Kawecka-Jaszcz K. Cardiovascular changes during chronic hypertensive states. Pediatr Nephrol 2014; 29(9): 1507–1516. doi: 10.1007/s00467-013-2614-5
10. Buyon JP, Cohen AP. А highlight from the LUPUS 2014 meeting: eight great ideas. Lupus Sci Med 2015; 2(1): e000087. Published online 2015 Jun 30. doi: 10.1136/lupus-2015-000087
11. Kazyra IA, Sukalo AV. Faktoryi progressirovaniya vtorichnyih glomerulonefritov u detey. Nefrologiya 2017;4 (21): 68–72] DOI: http://dx.doi.org/10.24884/1561-6274-2017-21-4-73-78
Review
For citations:
Kazyra I.A., Sukalo A.V. CARDIOMETABOLIC RISK FACTORS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS, LUPUS NEPHRITIS. Nephrology (Saint-Petersburg). 2018;22(3):26-32. (In Russ.) https://doi.org/10.24884/1561-6274-2018-22-3-26-32
Views:
729
Email this article 